Insulet Corporation
Insulet Corporation Announces Strong Q4 and FY 2024 Financial Results
Summary
Insulet Corporation reported significant financial improvements for the fourth quarter and full year of 2024, with revenue increasing by 17.2% and 22.1% respectively. The company achieved a record-breaking full-year revenue of over $2 billion and exceeded its growth and margin objectives. The strong performance was driven by robust demand for its Omnipod products, particularly the Omnipod 5, which is now available to both type 1 and type 2 patients in the U.S. and is expanding internationally. Insulet also provided guidance for 2025, expecting revenue growth of 16% to 20%.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement